Nephrology - Global Cardiology Academy

1-16 of 65

CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
MinuteCE®
CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
Ellie Kelepouris, MD, FACP, FAHA; Pauline A. Swift, PhD
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Pauline A. Swift, PhD
1.00 program credit
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
MinuteCE®
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
Nihar R. Desai, MD, MPH; Pauline A. Swift, PhD
1.00 program credit
- Nihar R. Desai, MD, MPH
- Pauline A. Swift, PhD
1.00 program credit
Potassium Binders to Optimize GDMT Therapy in HFrEF
Potassium Binders to Optimize GDMT Therapy in HFrEF
MinuteCE®
Potassium Binders to Optimize GDMT Therapy in HFrEF
Nihar R. Desai, MD, MPH; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- Nihar R. Desai, MD, MPH
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
MinuteCE®
The Potassium Shift: Individualizing Hyperkalemia Management With Modern Oral Potassium Binders
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 credit 8 episodes
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
- Ellie Kelepouris, MD, FACP, FAHA
- Pauline A. Swift, PhD
1.00 credit 8 episodes
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
MinuteCE®
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 program credit
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
1.00 program credit
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
MinuteCE®
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
James Burton, DM, FRCP; Pauline A. Swift, PhD
1.00 program credit
- James Burton, DM, FRCP
- Pauline A. Swift, PhD
1.00 program credit
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
MinuteCE®
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
James Burton, DM, FRCP; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
MinuteCE®
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
MinuteCE®
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 program credit
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
1.00 program credit
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Diabetes and Endocrinology
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Katherine Tuttle, MD
- Katherine Tuttle, MD
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Diabetes and Endocrinology
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Csaba P. Kovesdy, MD
- Csaba P. Kovesdy, MD
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Nephrology
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Peter Rossing, MD, DMSc
- Peter Rossing, MD, DMSc
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
CME/CE
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
- Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
CME/CE
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Brendon Neuen, MBBS, PhD; Katherine Tuttle, MD
0.25 credits
- Brendon Neuen, MBBS, PhD
- Katherine Tuttle, MD
0.25 credits
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart Matters
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD; Payal Kohli, MD, FACC
- Shelina Ramnarine, PhD
- Payal Kohli, MD, FACC
Understanding Residual Cardiovascular Risk in CKD and T2D
Understanding Residual Cardiovascular Risk in CKD and T2D
Diabetes Discourse
Understanding Residual Cardiovascular Risk in CKD and T2D
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH

Prev
1
2
3
4
5
Next

1/5